Tag: Bone metastasis

While osteonecrosis of the jaw (ONJ) is a serious and rare side effect, studies indicate that its incidence with high-dose Xgeva (denosumab) used for cancer treatment is higher than previously thought and appears to increase with longer treatment duration. A significant risk of **osteonecrosis of the jaw with Xgeva** exists, especially in patients with pre-existing dental issues or those undergoing invasive dental procedures.

According to the National Cancer Institute, Xgeva (denosumab) is a monoclonal antibody used to prevent or treat specific bone problems in cancer patients. It helps to reduce the risk of fractures, spinal cord compression, and other skeletal-related events.